Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, reported its second quarter 2025 financial results, showing significant changes compared to the same period in 2024. The company reported total revenues of $2.8 million for the three months ended June 30, 2025, marking a net increase of $1.4 million from $1.4 million in the same quarter the previous year. This increase was primarily driven by higher collaboration revenue recognized from deferred revenues under the Roche Agreement and the termination of the VAC platform-related collaboration agreement. The net loss attributable to Lineage for the second quarter of 2025 was $30.5 million, compared to a net loss of $5.8 million for the same period in 2024. The change was mainly due to a loss on impairment expense related to a 2019 acquisition and the quarterly fair value remeasurement of warrant liabilities. Lineage's financial position at the end of the quarter showed cash, cash equivalents, and marketable securities totaling $42.3 million, which the company expects will support its planned operations into the first quarter of 2027. The company continues to focus on developing novel allogeneic cell therapies for serious neurological and ophthalmic conditions.